Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer and BioNTech announced that their COVID-19 vaccine, with a third 3-µg dose for children under 5, met all immunobridging criteria for Emergency Use Authorization. A trial involving 1,678 children showed a favorable safety profile similar to placebo, with vaccine efficacy of 80.3% against symptomatic COVID-19 during the Omicron variant's surge. The companies plan to submit updated data to the FDA and other global regulators soon. The trial aims to provide strong protection against COVID-19 in young children, building on previous successful adult and adolescent studies.
The U.S. FDA has expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to include a booster dose for children aged 5 to 11. This booster, a 10-µg dose, can be administered at least five months after the second dose. Over 8 million children in this age group have completed the primary series. Data from clinical trials showed a strong immune response against both the Omicron variant and the wild-type virus, with no new safety issues reported.
Astellas Pharma will present 13 abstracts at the 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress, focusing on advanced and rare cancers, including prostate and pancreatic cancers. Highlights include findings from Phase 3 and 2 trials for therapies like enfortumab vedotin and zolbetuximab. Presentations aim to enhance treatment strategies for metastatic cancers. Astellas emphasizes its commitment to advancing oncology through innovative research and strategic collaborations, particularly with Pfizer on enzalutamide.
Pfizer has announced its acquisition of Biohaven, the maker of NURTEC® ODT, for approximately $11.6 billion. Shareholders will receive $148.50 per share in cash and shares in a new company retaining Biohaven's non-CGRP assets. The acquisition enhances Pfizer's Internal Medicine pipeline, focusing on migraine treatments with high market potential. NURTEC is already the leading migraine therapy in the U.S. The deal includes the purchase of Biohaven's CGRP programs and is expected to close by early 2023, pending approvals.
Pfizer (PFE) reported strong Q1 2022 revenues of $25.7 billion, marking an 82% operational growth. Excluding COVID-related revenues from Comirnaty and Paxlovid, operational growth was 2%. Reported diluted EPS was $1.37, with an adjusted EPS of $1.62. Despite challenges from foreign exchange impacts, Pfizer reaffirms its full-year revenue guidance of $98-102 billion and adjusted EPS of $6.25-6.45. The company has also begun share repurchases, totaling $2 billion in Q1. Key developments include continued success in vaccine distribution and ongoing clinical trials.
MOBItalks returns to New York on May 14, 2022, focusing on alternative wellness and community empowerment for Black gay men. Presented by ViiV Healthcare and the Mobilizing Our Brothers Initiative (MOBI), the event features speakers and provides networking opportunities. Attendees can enjoy free professional headshots and brunch by Cornbread26 Food Co. MOBI, active since 2017, aims to enhance personal development and community wellness, having contributed over $1 million to the Black queer community. For registration, visit mobi-nyc.com/nyctalks.
Pfizer Inc. (NYSE: PFE) has declared a quarterly cash dividend of $0.40 per share, scheduled for payment on June 10, 2022. This dividend will benefit shareholders of record by May 13, 2022. Notably, this marks the 334th consecutive dividend payment by Pfizer, showcasing the company's commitment to returning value to its investors.
Pfizer (NYSE: PFE) and Biohaven (NYSE: BHVN) announced the European Commission's marketing authorization for VYDURA® (rimegepant), the first medication approved for both acute and prophylactic treatment of migraines in adults. VYDURA® is an orally disintegrating tablet that targets a significant unmet need for migraine treatment in the EU, affecting around one in ten people. Clinical studies demonstrate its efficacy in reducing migraine symptoms and the frequency of attacks. The approval covers all 27 EU countries, with local reimbursement to follow.
Valneva SE and Pfizer reported positive Phase 2 results for their Lyme disease vaccine candidate, VLA15, showing a strong immunogenic response in participants aged 5-17. One month post-vaccination, pediatric participants demonstrated better immunogenicity compared to adults. The safety profile was consistent with earlier adult trials, with no serious adverse events noted. Both companies plan to include pediatric participants in the upcoming Phase 3 trial, set to begin in Q3 2022, pending regulatory approval.
Pfizer Inc. (NYSE: PFE) will hold its 2022 Annual Meeting of Shareholders virtually on April 28, 2022, starting at 9:00 a.m. EDT. Shareholders should log in at 8:45 a.m. EDT using their control numbers to participate fully. Questions can be submitted in advance until 5:00 p.m. EDT on April 26. Guests can listen without a control number. The webcast will be accessible for one year post-meeting. Shareholders can find registration details at www.meetnow.global/MWPVZT2.